TrialTransplantation and cellular therapy2023

Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma.

Marie José Kersten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.